Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

885 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

93 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03417895 2024-08-07

PASSION

Phase 2 Completed

59 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3 Completed

543 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02329860 2024-01-22

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Phase 3 Completed

400 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Phase 1 Completed

30 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04322552 2022-11-07

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Phase 1 Completed

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04457180 2022-10-26

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Phase 1 Completed

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02711969 2022-07-22

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Phase 1 Completed

6 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02764268 2022-03-11

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Phase NA Completed

60 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01497704 2017-10-02

Dose-Escalation and Safety Trial of YN968D1

Phase 1/2 Completed

55 enrolled

Tumor-Agnostic

Neoplasms

NCT02836171 2017-02-27

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms

NCT02836821 2017-02-27

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms

NCT01512745 2016-10-17

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 3 Completed

267 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT01531777 2015-04-03

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01270386 2012-02-10

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2 Completed

136 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

PASSION

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Dose-Escalation and Safety Trial of YN968D1

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer